EpiPen price hikes lead to overpayment settlement

EpiPen box

Rising drug prices were a hot-button issue this year, particularly in the wake of the scandal surrounding Martin Shkreli, who made a name for himself in 2015 for jacking up the price of a generic AIDS medication. Since then, several companies have come under fire for precipitous price hikes. One of those companies was Mylan, which raised the price of EpiPens more than 400% since 2009.

That controversy quickly transitioned into concerns that Mylan had misclassified EpiPens, translating to millions in overpayments. Senators called on the DOJ to investigate the misclassification, and two weeks later, Mylan agreed to a $465 million settlement.

Sen. Chuck Grassley, R-Iowa, called for hearing with the Senate Judiciary Committee to review the settlement, but representatives from the Justice Department, the Centers for Medicare & Medicaid Services and Mylan all declined to appear, forcing Grassley to consider compelling them to testify. Depending on whether he follows through on that, this case could have plenty more twists in store.

EpiPen price hikes lead to overpayment settlement

Suggested Articles

Silicon Valley giants are building software and technology tools to serve as trusted healthcare resources in the ongoing COVID-19 outbreak.

An advisory group to ONC is standing up a coronavirus task force to tackle privacy and interoperability issues impeding frontline clinicians.

The coronavirus pandemic puts a spotlight on some of the biggest risks for states seeking to roll out Medicaid block grants, a new analysis shows.